{"entity":{"id":"eb-car30-nk","kind":"drug","name":"EB-CAR30-NK","aka":[],"tldr":"EB-CAR30-NK is an experimental CAR-NK cell therapy from Beijing Biotech in phase 2 trials for thymoma and thymic carcinoma, aimed at CD30.","summary":"EB-CAR30-NK is a CAR-NK cell therapy developed by Beijing Biotech. Its target is CD30. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in thymoma and thymic carcinoma. The largest, NCT07598955, plans to enrol 36 participants with primary completion expected 2027-06-14. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of EB-CAR30-NK","url":"https://clinicaltrials.gov/search?intr=EB-CAR30-NK"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["thymic-epithelial"],"sections":[],"technologies":[],"targets":["cd30"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07598955"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"CAR-NK cell therapy","mechanism":"CAR-NK cell therapy directed at CD30, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/eb-car30-nk/","neighbours":{"cancer":[{"id":"thymic-carcinoma","kind":"cancer","name":"Thymic carcinoma","route":"/cancers/thymic-carcinoma/"},{"id":"thymoma","kind":"cancer","name":"Thymoma (WHO types A, AB, B1, B2 and B3)","route":"/cancers/thymoma/"},{"id":"thymic-epithelial","kind":"cancer","name":"Thymoma and thymic carcinoma","route":"/cancers/thymic-epithelial/"}],"target":[{"id":"cd30","kind":"target","name":"CD30","route":"/targets/cd30/"}],"trial":[{"id":"nct07598955","kind":"trial","name":"Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma","route":"/trials/nct07598955/"}]}}